Skip to main content
SpringerLink
Log in

Metabolism, Pathophysiology, and Clinical Considerations of Iron Overload, a Comprehensive Review

  • Chapter
  • First Online:
Essentials of Blood Product Management in Anesthesia Practice

Abstract

Transfusion has many benefits in certain pathological states and can be lifesaving; however, it can also have unwanted effects. This chapter provides a comprehensive review of iron metabolism and overload related to blood transfusion. Iron chelation therapy remains the standard of care for managing transfusion-related iron overload. Clinical investigations into refining these therapies to make them more effective, convenient, and tolerable are ongoing. Research into developing agents to modify previously untargeted aspects of iron metabolism is also being evaluated. Evidence suggests that exogenous transferrin may help normalize NTBI levels and curb the toxic effects of iron overload. Targeting hepcidin to influence iron absorption and mobilization is also being studied. Further refinement of these treatments should provide useful adjuncts and alternatives to existing options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fastag E, Varon J, Sternbach G. Richard Lower: the origins of blood transfusion. J Emerg Med. 2013;44(6):1146–50.

    Article  PubMed  Google Scholar 

  2. Learoyd P. The history of blood transfusion prior to the 20th century-part 2. Transfus Med. 2012;22(6):372–6.

    Article  CAS  PubMed  Google Scholar 

  3. Passerini HM. Contemporary transfusion science and challenges. AACN Adv Crit Care. 2019;30(2):139–50.

    Article  PubMed  Google Scholar 

  4. Blood Needs & Blood Supply [Internet]. 2019. Available from: https://www.redcrossblood.org/donate-blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html.

  5. Goel R, Chappidi MR, Patel EU, Ness PM, Cushing MM, Frank SM, et al. Trends in red blood cell, plasma, and platelet transfusions in the United States, 1993–2014. JAMA J Am Med Assoc. 2018;319(8):825–7.

    Article  Google Scholar 

  6. Tan SY, Graham C. Karl Landsteiner (1868–1943): originator of ABO blood classification. Singap Med J. 2013;54(5):243–4.

    Article  Google Scholar 

  7. Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North Am. 2005;23(2):241–52, v.

    Article  PubMed  Google Scholar 

  8. Goodnough LT, Brecher ME, Kantner MH, AuBochon JP. Transfusion medicine. First of two parts. Blood transfusion. N Engl J Med. 1999;340(6):438–47. https://doi.org/10.1056/NEJM199902113400606.

  9. Barty R, Jamula E, Wang G, Liu Y, Leber B, Heddle N; UHA. Transfusion-related iron overload: a covert risk of supportive cancer care. Blood. 2013;122(21):3656. https://doi.org/10.1182/blood.V122.21.3656.3656.

  10. Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int. 2017;21:S6–S20.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Anderson GJ, Frazer DM. Current understanding of iron homeostasis. Am J Clin Nutr. 2017;106(Suppl 6):1559S–66S.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986–95.

    Article  CAS  PubMed  Google Scholar 

  13. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348–59.

    Article  CAS  PubMed  Google Scholar 

  14. Milic S, Mikolasevic I, Orlic L, Devcic E, Starcevic-Cizmarevic N, Stimac D, et al. The role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gao C, Li L, Chen B, Song H, Cheng J, Zhang X, et al. Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia. Patient Prefer Adherence. 2014;8:513–7.

    PubMed  PubMed Central  Google Scholar 

  16. Cascio MJ, DeLoughery TG. Anemia: evaluation and diagnostic tests. Med Clin N Am. 2017;101(2):263–84.

    Article  PubMed  Google Scholar 

  17. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol. 2016;172(4):512–23.

    Article  CAS  PubMed  Google Scholar 

  18. Porter J, Viprakasit V. Iron overload and chelation. In: Guidelines for the management of transfusion dependent thalassemia. 3rd ed. Nicosia: Thalassaemia International Federation; 2014. p. 42–97.

    Google Scholar 

  19. Cross JH, Bradbury RS, Fulford AJ, Jallow AT, Wegmüller R, Prentice AM, et al. Oral iron acutely elevates bacterial growth in human serum. Sci Rep. 2015;5:16670.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wood JC. Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol. 2007;82(12 Suppl):1132–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Elsayed ME, Sharif MU, Stack AG. Transferrin saturation: a body iron biomarker. Adv Clin Chem. 2016;75:71–97.

    Article  CAS  PubMed  Google Scholar 

  22. Fisher S, Brunskill S, Doree C, Gooding S, Chowdhury O, Roberts D. Desferrioxamine mesylate for managing transfusional iron overload in people with thalassaemia. Cochrane Database Syst Rev. 2013;(8).

    Google Scholar 

  23. Xia S, Zhang W, Huang L, Jiang H. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One. 2013;8(12):1–9.

    Google Scholar 

  24. Kwiatkowski JL. Management of transfusional iron overload – differential properties and efficacy of iron chelating agents. J Blood Med. 2011;2:135–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the management of transfusion dependent thalassemia (TDT). Thalass Int Fed. 2014;20(20):42–98.

    Google Scholar 

  26. Marsella M, Borgna-Pignatti C. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Hematol Oncol Clin North Am, Elsevier Inc. 2014;28(4):703–27.

    Article  Google Scholar 

  27. Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatr Clin North Am, Elsevier Inc. 2013;60(6):1393–406.

    Article  Google Scholar 

  28. Saliba AN, El Rassi FTA. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Expert Rev Hematol. 2016;9(2):151–68.

    Article  CAS  PubMed  Google Scholar 

  29. Kwiatkowski JL. Current recommendations for chelation for transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):107–14.

    Article  CAS  PubMed  Google Scholar 

  30. Remacha Á, Sanz C, Contreras E, De Heredia CD, Grifols JR, Lozano M, et al. Guidelines on haemovigilance of post-transfusional iron overload. Blood Transfus. 2013;11(1):128–39.

    PubMed  PubMed Central  Google Scholar 

  31. DailyMed – DEFEROXAMINE – deferoxamine mesylate injection, powder, lyophilized, for solution.

    Google Scholar 

  32. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657–69.

    Article  CAS  PubMed  Google Scholar 

  33. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364(2):146–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bollig C, Schell L, Rucker G, Allert R, Motschall E, Niemeyer C, et al. Deferasirox for managing iron overload in people with thalassaemia (Review). 2014;(2).

    Google Scholar 

  35. Huang W-F, Chou H-C, Tsai Y-W, Hsiao F-Y. Safety of deferasirox: a retrospective cohort study on the risks ofgastrointestinal, liver and renal events. Pharmacoepidemiol Drug Saf. 2014;23:1176–82.

    Article  CAS  PubMed  Google Scholar 

  36. DailyMed – EXJADE- deferasirox tablet, for suspension.

    Google Scholar 

  37. Pennell DJ, Porter JB, Piga A, Lai Y, El-beshlawy A, Belhoul KM, et al. Clinical trials and observations myocardial iron removal in b -thalassemia major (CORDELIA). 2018;123(10):1447–55.

    Google Scholar 

  38. Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. [Update of Cochrane Database Syst Rev. 2007;(3):CD004839; PMID: 17636775]. Cochrane Database Syst Rev. 2013;8:CD004839.

    Google Scholar 

  39. DailyMed – FERRIPROX- deferiprone tablet, film coated.

    Google Scholar 

  40. Hammond J, Thompson AA, Fogel MA, Hammond K, Kokroko J, Kwiatkowski JL. Combination oral chelation in adult patients with transfusion-dependent thalassemia and high iron burden. J Pediatr Hematol Oncol. 2019;41(1):E47–50.

    Article  PubMed  Google Scholar 

  41. Gomber S, Jain P, Sharma S, Narang M. Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian Pediatr. 2016;53(3):207–10.

    Article  PubMed  Google Scholar 

  42. Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, et al. Cardiovascular function and treatment in β-thalassemia major. Circulation. 2013;128(3):281–308.

    Article  CAS  PubMed  Google Scholar 

  43. Kwiatkowski J, Fedorowicz Z, Aird W. Transfusional iron overload. Dynamed. 2019:1–107. https://www.dynamed.com/condition/transfusional-iron-overload.

  44. Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017;177(5):703–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Fisher SA, Trivella M, Doree C, Fortin PM, Madgwick KV, Estcourt LJ, et al. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database Syst Rev. 2018;5(5):CD012349.

    PubMed  Google Scholar 

  46. Taher A, Vichinsky E, Khaled M, Cappellini MD, Viprakasit V. Guidelines for the management of non transfusion dependent thalassemia (NTDT). Thalass Int Fed. 2017;22(22):1–117.

    Google Scholar 

  47. Evidence-based management of sickle cell disease: expert panel, 2014. National Heart, Lung and Blood Institute. 2014. https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease.

  48. National Heart Lung and Blood Institute. The management of sickle cell disease. 2002. https://www.nhlbi.nih.gov/files/docs/guidelines/sc_mngt.pdf?

  49. Al-Kali A, Bejar R, Bennett JM, Hetty Carraway C; Clinic Cancer Center Stefan Barta MK; Þ Fox Chase Cancer Center M, et al. Myelodysplastic syndromes NCCN guidelines ® NCCN myelodysplastic syndromes panel members. 2017;15(1):60–87.

    Google Scholar 

  50. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83(11):858–61.

    Article  PubMed  Google Scholar 

  51. Killick SB, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164(4):503–25.

    Article  CAS  PubMed  Google Scholar 

  52. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.

    Article  PubMed  Google Scholar 

  53. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013:447–56.

    Article  PubMed  Google Scholar 

  54. Panch SR, Yau YY, West K, Diggs K, Sweigart T, Leitman SF. Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload. Transfusion. 2015;55(3):611–22.

    Article  CAS  PubMed  Google Scholar 

  55. Kelly S, Quirolo K, Marsh A, Neumayr L, Garcia A, Custer B. Erythrocytapheresis for chronic transfusion therapy in sickle cell disease: survey of current practices and review of the literature. Transfusion. 2016;56(11):2877–88.

    Article  PubMed  Google Scholar 

  56. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155–67.

    Article  PubMed  Google Scholar 

  57. Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Kumfu S, Chattipakorn S, Chattipakorn N. T-type and L-type calcium channel blockers for the treatment of cardiac iron overload: an update. J Cardiovasc Pharmacol. 2017;70(5):277–83.

    Article  CAS  PubMed  Google Scholar 

  59. Sadaf A, Hasan B, Das JK, Colan S, Alvi N. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev. 2018;7(7):CD011626.

    PubMed  Google Scholar 

  60. Aydinok Y, Kattamis A, Viprakasit V. Current approach to iron chelation in children. Br J Haematol. 2014;165(6):745–55.

    Article  CAS  PubMed  Google Scholar 

  61. Yassin MA, Soliman AT, De Sanctis V, Hussein RM, Al-Okka R, Kassem N, et al. Jadenu ® substituting Exjade ® in iron overloaded β-thalassemia major (BTM) patients: a preliminary report of the effects on the tolerability, serum ferritin level, liver iron concentration and biochemical profiles. Mediterr J Hematol Infect Dis. 2018;10(1):e2018064.

    PubMed  PubMed Central  Google Scholar 

  62. Shah NR. Advances in Iron chelation therapy: transitioning to a new oral formulation. Drugs Context. 2017;6:212502.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Li H, Rybicki AC, Suzuka SM, Von Bonsdorff L, Breuer W, Hall CB, et al. Transferrin therapy ameliorates disease in Β-thalassemic mice. Nat Med. 2010;16(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  64. Liu J, Sun B, Yin H, Liu S. Hepcidin: a promising therapeutic target for iron disorders. Medicine (United States). 2016;95(14):e3150.

    CAS  Google Scholar 

  65. Parrow NL, Gardenghi S, Rivella S. Prospects for a hepcidin mimic to treat β-thalassemia and hemochromatosis. Expert Rev Hematol. 2011;4(3):233–5.

    Article  PubMed  Google Scholar 

  66. Breda L, Gardenghi S, Guy E, Rachmilewitz EA, Weizer-Stern O, Adamsky K, et al. Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in β-thalassemia. Ann N Y Acad Sci. 2005;1054:417–22.

    Article  CAS  PubMed  Google Scholar 

  67. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol. 2011;54(1):173–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, LSUHSC New Orleans, New Orleans, LA, USA

    Andrew Jesse Garcia & Chikezie N. Okeagu

  2. George Washington University School of Medicine and Health Sciences, Washington, DC, USA

    Andrew Jesse Garcia

  3. Department of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University School of Medicine-Shreveport, Shreveport, LA, USA

    Alan David Kaye

  4. LSU Health Shreveport School of Medicine, New Orleans, LA, USA

    Alan David Kaye

  5. Tulane School of Medicine, New Orleans, LA, USA

    Alan David Kaye

  6. Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

    Alaa Abd-Elsayed

Authors
  1. Andrew Jesse Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chikezie N. Okeagu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan David Kaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alaa Abd-Elsayed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan David Kaye .

Editor information

Editors and Affiliations

  1. NYU-Grossman School of Medicine, Department of Anesthesiology, New York, NY, USA

    Corey S. Scher

  2. Departments of Anesthesiology and Pharmacology Toxicology, and Neurosciences, Louisiana State University School of Medicine-Shreveport, Shreveport, LA, USA

    Alan David Kaye

  3. Department of Anesthesiology and Perioperative Medicine, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA

    Henry Liu

  4. NYU Grossman School of Medicine, Department of Anesthesiology, Perioperative Care and Pain Medicine, New York, NY, USA

    Seth Perelman

  5. NYU-Grossman School of Medicine, Department of Anesthesiology, New York, NY, USA

    Sarah Leavitt

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Garcia, A.J., Okeagu, C.N., Kaye, A.D., Abd-Elsayed, A. (2021). Metabolism, Pathophysiology, and Clinical Considerations of Iron Overload, a Comprehensive Review. In: Scher, C.S., Kaye, A.D., Liu, H., Perelman, S., Leavitt, S. (eds) Essentials of Blood Product Management in Anesthesia Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-59295-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-59295-0_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-59294-3

  • Online ISBN: 978-3-030-59295-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation